Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | PPID | Q08752 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.44 |
| ▸ | CAD | P27708 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5813379 | 1.00 | ALDH1A1 (0.60) | ALDH1A1PPIDTAS1R3TAS1R1CAD | |
| SCHEMBL5814137 | 0.85 | ALDH1A1 (0.56) | ALDH1A1PPIDTAS1R3TAS1R1BIRC2 | |
| SCHEMBL5814142 | 0.85 | ALDH1A1 (0.56) | ALDH1A1PPIDTAS1R3TAS1R1BIRC2 | |
| SCHEMBL16316785 | 0.85 | PPID (0.48) | ALDH1A1PPIDTAS1R3TAS1R1CAD | |
| SCHEMBL6900424 | 0.85 | PPID (0.50) | ALDH1A1PPIDTAS1R3TAS1R1CAD | |
| SCHEMBL5812880 | 0.84 | ALDH1A1 (0.64) | ALDH1A1TAS1R3TAS1R1BIRC2POLB | |
| SCHEMBL245758 | 0.84 | ALDH1A1 (0.64) | ALDH1A1TAS1R3TAS1R1BIRC2POLB | |
| SCHEMBL11316551 | 0.84 | ALDH1A1 (0.64) | ALDH1A1TAS1R3TAS1R1BIRC2POLB | |
| SCHEMBL14902193 | 0.84 | L3MBTL1 (0.50) | ALDH1A1PPIDTAS1R3TAS1R1CAD | |
| SCHEMBL8310678 | 0.83 | PPID (0.49) | ALDH1A1PPIDTAS1R3TAS1R1CAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015000076-A9 | PHOTOCHEMICAL PROCESS FOR THE FLUORINATION OF AN ORGANIC COMPOUND HAVING AN UNACTIVATED SP3 C-H BOND | ALECTOS THERAPEUTICS INC. (CA) | 2015-08-06 | — | — | WO | claimed |
| WO-2015000076-A1 | PHOTOCHEMICAL PROCESS FOR THE FLUORTNATION OF AN ORGANIC COMPOUND HAVING AN UNACTIVATED SP3 C-H BOND | ALECTOS THERAPEUTICS INC. (CA) | 2015-01-08 | — | — | WO | claimed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| US-20250352496-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPHARMA LTD (KY) | 2025-11-20 | — | — | US | disclosed |
| US-12396966-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | XWPharma Ltd. (KY) | 2025-08-26 | — | — | US | disclosed |
| EP-4559522-A2 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2025-05-28 | — | — | EP | disclosed |
| EP-4384145-B1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPHARMA LTD (KY) | 2025-04-23 | — | — | EP | disclosed |
| EP-4384145-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2024-06-19 | — | — | EP | disclosed |
| US-20230285325-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-09-14 | — | — | US | disclosed |
| US-11690811-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | XWPharma Ltd. (KY) | 2023-07-04 | — | — | US | disclosed |
| US-20230098084-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-03-30 | — | — | US | disclosed |
| WO-2017093544-A1 | ALKYNYL PHOSPHINE GOLD COMPLEXES FOR TREATING BACTERIAL INFECTIONS | AUSPHERIX LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| WO-2015000076-A9 | PHOTOCHEMICAL PROCESS FOR THE FLUORINATION OF AN ORGANIC COMPOUND HAVING AN UNACTIVATED SP3 C-H BOND | ALECTOS THERAPEUTICS INC. (CA) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015000076-A9 | PHOTOCHEMICAL PROCESS FOR THE FLUORINATION OF AN ORGANIC COMPOUND HAVING AN UNACTIVATED SP3 C-H BOND | ALECTOS THERAPEUTICS INC. (CA) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015000076-A1 | PHOTOCHEMICAL PROCESS FOR THE FLUORTNATION OF AN ORGANIC COMPOUND HAVING AN UNACTIVATED SP3 C-H BOND | ALECTOS THERAPEUTICS INC. (CA) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015000076-A1 | PHOTOCHEMICAL PROCESS FOR THE FLUORTNATION OF AN ORGANIC COMPOUND HAVING AN UNACTIVATED SP3 C-H BOND | ALECTOS THERAPEUTICS INC. (CA) | 2015-01-08 | — | — | WO | disclosed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | disclosed |
| US-RE29843-E | Substituted thiazoles and flavoring processes and products produced thereby | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690811-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | OPRK1, KCNK5, KCNK17 | ALDH1A1 2360/4885PPID 3287/4885TAS1R3 925/4885 |
| US-12396966-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | OPRK1, KCNK5, KCNK17 | ALDH1A1 2360/4885PPID 3287/4885TAS1R3 925/4885 |
| US-20250352496-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | OPRK1, KCNK5, KCNK17 | ALDH1A1 2360/4885PPID 3287/4885TAS1R3 925/4885 |
| US-20230098084-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | OPRK1, KCNK5, KCNK17 | ALDH1A1 2360/4885PPID 3287/4885TAS1R3 925/4885 |
| US-20230285325-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | OPRK1, KCNK5, KCNK17 | ALDH1A1 2360/4885PPID 3287/4885TAS1R3 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.